For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Alliance A041702

Trial Overview

Official Title

A Randomized Phase III study of Ibrutinib Plus Obinutuzumab versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 years of age) with Chronic Lymphocytic Leukemia (CLL)

Study Purpose

To compare the usual treatment alone (Ibrutinib plus Obinutuzumab) to using Venetoclax plus the usual treatment. The addition of Venetoclax to the usual treatment could prevent chronic lymphocytic leukemia from returning.

Diagnosis

Chronic Lymphocytic Leukemia

Eligibility

Central FISH blood submission.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

  • Group 1: Ibrutinib plus Obinutuzumab
  • Group 2: Ibrutinib plus Obinutuzumab plus Venetoclax (study drug)

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Male or Female
Age
≥ 70 years
Enrollment Status
Recruiting
Phase
Phase III
Methodist Health System Trial Code
A041702
Related Specialties